肿瘤细胞治疗研究
FRONTIER PAPERS
A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.
嵌合抗原受体（CAR）T 细胞疗法对神经母细胞瘤（NB）等实体瘤的疗效有限。
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
B 细胞急性淋巴细胞白血病 (B-ALL) 是儿童期最常见的癌症。
Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma.
Glypican-2 (GPC2) 和双唾液酸神经节苷脂 GD2 是神经母细胞瘤中经过验证的 CAR T 细胞靶点，但持久的临床缓解仍然有限。
Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clini
初步临床经验表明，针对儿童和年轻成人 CNS 肿瘤的 CAR-T 细胞疗法具有生物学活性且临床可行，其毒性特征独特但可控。
Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.
我们的结果表明，瘤内递送的瞬时 mRNA CAR T 细胞具有实用价值，能够以明确的半衰期提供有效的肿瘤杀伤，并允许对剂量和潜在副作用进行调控。
Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens.
双特异性抗体和CAR-T 细胞是临床使用中最有效的癌症免疫治疗药物之一，但大多数癌症仍然难以靶向。
Label-free metabolic imaging monitors the fitness of chimeric antigen receptor T cells.
由于免疫抑制性肿瘤微环境和复杂的生产工艺，实体瘤的嵌合抗原受体（CAR）T 细胞治疗面临挑战。
CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.
本综述探讨了将 CAR-T 细胞疗法与重建性肿瘤外科手术整合，用于治疗外周实体瘤，包括黑色素瘤、肉瘤、乳腺癌和头颈部癌。
Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma.
嵌合抗原受体（CAR）T 细胞对包括神经母细胞瘤在内的实体瘤疗效有限。
Engineering sonogenetic EchoBack-CAR T cells.
用于实体瘤的嵌合抗原受体（CAR）T 细胞疗法面临脱靶毒性、耗竭以及 T 细胞持久性有限等挑战。
MEMBER ACCOUNT
登录成功会直接打开下一页。
